Please use this identifier to cite or link to this item:
|Title:||Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients.|
|Authors:||Bishop, Emma;Melvani, Sharmila;Howden, Benjamin P;Charles, Patrick G P;Grayson, M Lindsay|
|Affiliation:||Infectious Diseases Department, Austin Health, Studley Rd., Heidelberg, Victoria 3084, Australia. Emma.Bishop@austin.org.au|
|Citation:||Antimicrobial Agents and Chemotherapy; 50(4): 1599-602|
|Abstract:||We assessed the toxicity and clinical outcomes associated with linezolid therapy (mean duration, 29+/-28 days; range, 8 to 185 days) in 44 patients with serious gram-positive infections. Although a clinical cure was achieved in 73% of the cases, 28/44 (64%) had adverse reactions (thrombocytopenia, n=13; anemia, n=7; gastrointestinal, n=12; peripheral neuropathy, n=1; serotonin syndrome, n=1), such that a systematic monitoring protocol was developed.|
|Internal ID Number:||16569895|
Aged, 80 and over
Anti-Infective Agents.adverse effects
Gram-Positive Bacterial Infections.drug therapy
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.